CA3045041A1 - Hsp90-targeting conjugates and formulations thereof - Google Patents

Hsp90-targeting conjugates and formulations thereof Download PDF

Info

Publication number
CA3045041A1
CA3045041A1 CA3045041A CA3045041A CA3045041A1 CA 3045041 A1 CA3045041 A1 CA 3045041A1 CA 3045041 A CA3045041 A CA 3045041A CA 3045041 A CA3045041 A CA 3045041A CA 3045041 A1 CA3045041 A1 CA 3045041A1
Authority
CA
Canada
Prior art keywords
conjugate
acid
particles
poly
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3045041A
Other languages
English (en)
French (fr)
Inventor
Benoit Moreau
Brian H. White
Mark T. Bilodeau
Mary SIMCOX
Kerry Whalen
Leila Alland
Richard Wooster
Rajesh R. Shinde
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
TVA ABC LLC
Original Assignee
Tarveda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarveda Therapeutics Inc filed Critical Tarveda Therapeutics Inc
Publication of CA3045041A1 publication Critical patent/CA3045041A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3045041A 2016-12-14 2017-12-14 Hsp90-targeting conjugates and formulations thereof Abandoned CA3045041A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662434282P 2016-12-14 2016-12-14
US62/434,282 2016-12-14
US201762449260P 2017-01-23 2017-01-23
US62/449,260 2017-01-23
US201762487726P 2017-04-20 2017-04-20
US62/487,726 2017-04-20
PCT/US2017/066361 WO2018112176A1 (en) 2016-12-14 2017-12-14 Hsp90-targeting conjugates and formulations thereof

Publications (1)

Publication Number Publication Date
CA3045041A1 true CA3045041A1 (en) 2018-06-21

Family

ID=62559344

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045041A Abandoned CA3045041A1 (en) 2016-12-14 2017-12-14 Hsp90-targeting conjugates and formulations thereof

Country Status (7)

Country Link
US (2) US11241500B2 (OSRAM)
EP (1) EP3554558A4 (OSRAM)
JP (1) JP2020503289A (OSRAM)
CN (1) CN110049783A (OSRAM)
AU (1) AU2017376766A1 (OSRAM)
CA (1) CA3045041A1 (OSRAM)
WO (1) WO2018112176A1 (OSRAM)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2018222987A1 (en) * 2017-06-01 2018-12-06 Tarveda Therapeutics, Inc. Targeted constructs
AU2018386218A1 (en) * 2017-12-14 2020-07-02 Tva (Abc), Llc HSP90-targeting conjugates and formulations thereof
WO2020056205A1 (en) * 2018-09-14 2020-03-19 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CN109400597B (zh) * 2018-11-08 2020-07-28 西安交通大学 一种基于vegfr-2抑制剂abt-869的蛋白降解靶向嵌合体及制备方法和应用
AU2020253385B2 (en) * 2019-04-03 2025-06-26 Fusion Pharmaceuticals Inc. Hsp90-binding conjugates and formulations thereof
WO2020206608A1 (en) * 2019-04-09 2020-10-15 Ranok Therapeutics (Hangzhou) Co., Ltd. Methods and compositions for targeted protein degradation
CN112279863A (zh) * 2019-07-25 2021-01-29 华东师范大学 Hsp90抑制剂与喜树碱衍生物的偶联物及其制备方法与应用
WO2022047008A1 (en) * 2020-08-26 2022-03-03 Tarveda Therapeutics, Inc. Hsp90-binding conjugates and formulations thereof
CN112168825A (zh) * 2020-10-30 2021-01-05 江苏大学 含hsp90抑制剂和parp抑制剂的药物组合物
CN112641949A (zh) * 2021-01-11 2021-04-13 深圳市人民医院(深圳市呼吸疾病研究所) 一种含有pi3k抑制剂的药物组合物及其应用
CN115286643B (zh) * 2022-09-02 2023-09-01 南京大学 蛋白质靶向降解化合物及其制备方法和应用
WO2025166213A1 (en) * 2024-02-01 2025-08-07 Fulgent Pharma Llc Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
WO2025214403A1 (zh) * 2024-04-12 2025-10-16 四川科伦博泰生物医药股份有限公司 抗体药物偶联物、组合物及其用途和方法
WO2025249944A1 (ko) * 2024-05-29 2025-12-04 주식회사 매직불릿테라퓨틱스 열충격 단백질 조절 접합체 및 이의 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608053B2 (en) * 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
AU2003293310B2 (en) 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
AU2007297212B8 (en) * 2006-09-15 2011-04-28 Pfizer Products Inc. Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
AR064106A1 (es) 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US20140079636A1 (en) * 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
US20140187501A1 (en) * 2012-12-28 2014-07-03 Blend Therapeutics, Inc. Targeted Conjugates Encapsulated in Particles and Formulations Thereof
EP3164420A4 (en) * 2014-06-30 2018-05-23 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof
EP3423112A4 (en) * 2016-02-29 2020-02-26 Madrigal Pharmaceuticals, Inc. HSP9 INHIBITOR-ACTIVE CONJUGATES

Also Published As

Publication number Publication date
US11241500B2 (en) 2022-02-08
AU2017376766A1 (en) 2019-06-06
EP3554558A4 (en) 2020-10-28
US20220096640A1 (en) 2022-03-31
US20200085960A1 (en) 2020-03-19
WO2018112176A1 (en) 2018-06-21
JP2020503289A (ja) 2020-01-30
EP3554558A1 (en) 2019-10-23
CN110049783A (zh) 2019-07-23

Similar Documents

Publication Publication Date Title
US20220096640A1 (en) Hsp90-targeting conjugates and formulations thereof
JP6932389B2 (ja) 標的化コンジュゲートならびにその粒子及び製剤
US20210000966A1 (en) Hsp90-targeting conjugates and formulations thereof
US20200078468A1 (en) Neurotensin receptor binding conjugates and formulations thereof
AU2013369982B2 (en) Targeted conjugates encapsulated in particles and formulations thereof
US11510910B2 (en) HSP90 targeted conjugates and particles and formulations thereof
CN108473538A (zh) Sstr靶向缀合物及其颗粒和制剂
WO2017210246A2 (en) Penicillamine conjugates and particles and formulations thereof
JP2018519283A (ja) 標的化コンジュゲートならびにその粒子および製剤
TW202222311A (zh) 結合熱休克蛋白９０（ｈｓｐ９０）之共軛體和彼之調製劑
WO2022235889A1 (en) Hsp90-binding conjugates and formulations thereof
US20200237746A1 (en) Hsp90 targeted conjugates and particle formulations thereof
WO2020056205A1 (en) Hsp90-targeting conjugates and formulations thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20240327